Update shared on 01 Dec 2025
Analysts raised their price target for Xeris Biopharma Holdings from $6 to $8, citing steady revenue growth and expectations for sustained cash generation as a result of the company’s expanding presence in the hypercortisolism market.
Analyst Commentary
Following recent quarterly results and the upward revision of the price target, analysts provided detailed insights regarding the valuation and execution outlook for Xeris Biopharma Holdings. Their commentary reflects both optimism about future growth and caution regarding certain operational aspects.
Bullish Takeaways
- Bullish analysts highlight the continued revenue growth, noting that actual quarterly revenues slightly exceeded consensus estimates. This reinforces confidence in the company’s commercial strategy.
- The expansion in the hypercortisolism market, particularly the strong performance of Recorlev, is seen as an important driver for long-term, sustainable cash generation.
- Upward price target revisions are primarily attributed to improved expectations for earnings stability, along with a demonstrated ability to capitalize on new market opportunities.
- Consistent execution in product launches and maintenance of steady gross margins have been cited as significant contributors to the improved valuation outlook.
Bearish Takeaways
- Bearish analysts remain cautious due to the firm's Neutral rating, pointing to uncertainties in the broader pharmaceutical market that could affect future sales growth or margin preservation.
- There is ongoing concern regarding competition within the hypercortisolism space, which could potentially limit further market share expansion for Recorlev.
- Some analysts note that, while the company reported earnings per share in line with expectations, the lack of significant upside in profitability metrics may slow further upward price revisions in the near term.
What's in the News
- Xeris Biopharma Holdings updated its full-year 2025 earnings guidance, projecting total revenue between $285 million and $290 million. This represents 42% growth at the midpoint compared to the previous year (Key Developments).
Valuation Changes
- Consensus Analyst Fair Value Estimate remains unchanged at $11.50 per share.
- Discount Rate has decreased marginally from 6.96% to 6.96%.
- Revenue Growth Projection holds steady at approximately 21.8% year-over-year.
- Net Profit Margin expectation is unchanged at roughly 20.2%.
- Future Price-to-Earnings (P/E) Ratio forecast remains stable at 29.38x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.